Pascal Soriot, CEO of Astrazeneca, says there will be less need for mergers and acquisitions as the company's internal drug pipeline is strong.
Mike Ward, global director of content at SCRIP Intelligence, says pharmaceutical companies could look towards the technology sector for interesting mergers, acquisitions or partnerships.
Pfizer's bid to take over U.K. pharmaceutical company AstraZeneca would have probably "fallen apart", Pascal Soriot, the firm's CEO, told CNBC.
American pharmaceutical giant has been pursuing AstraZeneca for some time, however CNBC's Catherine Boyle says it looks like the deal has "definitely receded".
Pfizer has seen off its six month cooling period before it can launch another bid for AstraZeneca, but will the American drugs giant continue its pursuit?
CNBC's Meg Tirrell, and Nancy Goodman, Kids v. Cancer founder, discuss the initiative to encourage drug companies to develop treatments for children with cancer and other rare diseases.
Kids facing cancer need access to promising — albeit unapproved — drugs, say these parents, who have faced the battle with their children firsthand.
Sanofi's global R&D President Dr. Elias Zerhouni, says he wouldn't trade his company's pipeline with anybody in the industry, and discusses the upcoming drug launches.
AstraZeneca said it had made good progress in developing a pipeline of new drugs.
NIH's Dr. Francis Collins and Milken Institute Chairman Mike Milken make the case for medical research funding to stop outbreaks like Ebola.
Shares of Zoetis are on the move after Actavis announced it is buying Allergan. Mark Schoenbaum, Evercore ISI senior managing director, discusses if the company could be bought.
Áine Slowey, senior analyst at Datamonitor Healthcare, discusses Actavis' decision to buy Allergan for $65.5 billion, saying that Actavis has demonstrated a "strong commitment" to R&D.
Allergan chairman & CEO David Pyott, explains why Allergan never engaged Valeant Pharmaceuticals and what's next for the newly combined companies.
CNBC's Jim Cramer speaks to Brent Saunders, Actavis CEO, and David Pyott, Allergan chairman & CEO, about the growth and R&D budget of the combined companies going forward.
CNBC's David Faber speaks to David Pyott, Allergan chairman & CEO, and Brent Saunders, Actavis CEO about their deal worth roughly $66 billion and what it means for shareholders.
Actavis is nearing a deal to acquire Allergan in a cash and stock deal worth more than $210 per Allergan share, sources tell CNBC.
Intercept Pharmaceuticals CEO Mark Pruzanski, provides insight to his company's efforts to tackle NASH, or nonalcoholic steatohepatitis, saying over 10 percent of the U.S. population is thought to have NASH. Pruzanski also weighs in on being a public company.
UK patients could soon be "prescribed" a smartphone application instead of a medical prescription when visiting their doctor.
Experts are meeting in Brussels to debate whether some materials like plastic bottles could be dangerous.
Discussing warning signs from Dendreon, and other worrisome companies, with Les Funtleyder, E Square Asset Management.